Correspondence case reports

The potential dangers of mephedrone in people with diabetes: a case report

  1. Mo Lee Wong1,
  2. Professor Richard IG Holt2,*

Article first published online: 13 JUL 2011

DOI: 10.1002/dta.316

Issue

Drug Testing and Analysis

Drug Testing and Analysis

Special Issue: New Psychoactive Substances

Volume 3, Issue 7-8, pages 464–465, July - August 2011

Additional Information

How to Cite

Wong, M. L. and Holt, R. I. (2011), The potential dangers of mephedrone in people with diabetes: a case report. Drug Test Analysis, 3: 464–465. doi: 10.1002/dta.316

Author Information

  1. 1

    Diabetes and Endocrinology, Southampton General Hospital, Southampton, UK

  2. 2

    Developmental Origins of Adult Health and Disease Division, University of Southampton School of Medicine, UK

*IDS Building (MP887), Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK.

Publication History

  1. Issue published online: 20 JUL 2011
  2. Article first published online: 13 JUL 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (41K)
Thumbnail image of graphical abstract

Mephedrone is a cathinone derivative that has been used as a ‘legal high’ but was re-classified in the UK as a class B (intermediate category) drug. This report describes an 18-year-old man with type 1 diabetes who developed ketoacidosis following self-reported mephedrone use. Cathinone compounds may directly increase the risk of diabetic ketoacidosis by stimulating the central nervous system but may also indirectly impair an individual's ability to manage their diabetes through changes in cognitive function and behaviour.

View Full Article (HTML) Get PDF (41K)